Kohlberg Kravis to Acquire RPS - Analyst Blog

By
A A A

Kohlberg Kravis Roberts & Co. L.P. ( KKR ) announced an agreement to purchase clinical research firm ReSearch Pharmaceutical Services Inc (RPS) from N.Y.-based global private equity firm, Warburg Pincus. This agreement marks Kohlberg Kravis Roberts' second investment in a contract research organization (CRO), within 2 months of its agreement to buy PRA International from California-based Genstar Capital LLC in Jun-end.

The transaction is expected to be completed in the third quarter of this year. Credit Suisse Group AG ( CS ), UBS AG ( UBS ) and Citigroup, Inc. ( C ) are acting as advisors for the deal.

Founded in 1998, ReSearch Pharmaceutical Services, which operates in over 64 countries, is a leader in outsourced clinical development services. The company is primarily known for its notable contribution in the Embedded model of functional clinical development outsourcing.

On completion of both the deals, Kohlberg Kravis Roberts plans to merge PRA International and ReSearch Pharmaceutical Services. PRA International's Chief Executive Officer Colin Shannon is expected to head the combined entity. ReSearch Pharmaceutical Services will operate as the Strategic Solutions Unit of PRA International.

For Kohlberg Kravis Roberts, the latest deal will mark its third healthcare investment in a little over the past one year. In Jun 2012, the company announced an investment in GenesisCare, an Australia-wide network of cancer and cardiovascular care centers. Since 1995, Kohlberg Kravis Roberts has invested about $9 billion in healthcare globally.

In the recent past, the pharmaceutical industry has witnessed many mergers, with 17 moderate to large deals taking place over the last 4 years. Clinical research service firms are either being acquired by private equity firms or are becoming public, with healthy investor demand. The CRO market is expected to be more profitable, given the rising number of pharmaceutical companies that are outsourcing the research necessary to enable drugs to meet regulatory standards.

Kohlberg Kravis Roberts currently carries a Zacks Rank #3 (Hold).



CITIGROUP INC (C): Free Stock Analysis Report

CREDIT SUISSE (CS): Free Stock Analysis Report

KKR & CO LP (KKR): Free Stock Analysis Report

UBS AG (UBS): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research




The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: Investing , Business , Stocks

Referenced Stocks: C , CS , KKR , UBS

Zacks.com

Zacks.com

More from Zacks.com:

Related Videos

Stocks

Referenced

74%
67%
88%
100%

Most Active by Volume

89,070,840
  • $17.26 ▲ 3.23%
78,931,485
  • $7.02 ▲ 4.46%
77,555,734
  • $6.70 ▲ 6.69%
77,025,346
  • $24.66 ▲ 0.69%
74,713,335
  • $101.80 ▲ 1.82%
72,324,726
  • $7.64 ▲ 0.79%
57,112,188
  • $17.84 ▲ 55.27%
53,321,397
  • $18.01 ▼ 4.46%
As of 12/17/2014, 04:15 PM


Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com